Simple Clinical Colitis Activity Index
Also known as: SCCAI
The Simple Clinical Colitis Activity Index (SCCAI) is a practical, bedside tool for assessing disease activity in ulcerative colitis and colonic Crohn's disease. Published in 1998 by Walmsley and colleagues, the SCCAI condenses disease assessment into six items that can be administered in a office visit without laboratory or endoscopic data. It provides rapid, reproducible quantification of disease severity and is ideal for frequent monitoring in routine clinical practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
SCCAI is ideal for routine office-based monitoring in established UC or colonic Crohn's disease. It is used at follow-up visits to assess response to therapy, guide dose adjustments, and detect flares. Because it requires neither endoscopy nor laboratory testing, SCCAI can be administered at every visit or even between-visit phone check-ins. It is not suitable for initial diagnostic assessment (which requires endoscopy and biopsy) but excels at longitudinal monitoring. In settings where Mayo Score endoscopy is performed (e.g., every 8–12 weeks), SCCAI bridges the gap for interim office assessments.
Strengths & limitations
- Practicality: Six items, no endoscopy or labs required; can be administered in 5 minutes at any office or phone visit.
- Frequent monitoring: Enables weekly or biweekly assessment without logistic burden, improving detection of early flares.
- Correlation with Mayo: SCCAI correlates well with Mayo Score (r ~0.8) and predicts endoscopic and clinical remission adequately for monitoring purposes.
- Reproducibility: Objective anchors (stool frequency counts, blood presence) minimize interrater variability.
- Lack of endoscopic component: SCCAI cannot discriminate between superficial mucosal erythema and severe ulceration; a patient with SCCAI <3 may still have active endoscopic disease.
- No laboratory integration: Does not incorporate inflammatory markers (CRP, ESR, fecal calprotectin); subclinical inflammation is not captured.
- Symptom-based bias: Patients on antidiarrheals or those with irritable bowel syndrome overlap may have low stool frequency despite active inflammation.
- Limited use in severe disease: SCCAI was not validated in hospitalized or severe UC requiring anti-TNF therapy; the Mayo Score is preferred for severe disease assessment.
Frequently asked
How does SCCAI compare to the Mayo Score?
SCCAI and Mayo Score correlate highly (r ~0.8–0.85) but measure different constructs. Mayo integrates clinical and endoscopic findings, providing objective mucosal assessment. SCCAI is purely clinical and does not require endoscopy. For remission definition in trials, Mayo ≤2 with endoscopic subscore ≤1 is preferred. For office monitoring, SCCAI is more practical. Consider using SCCAI between Mayo assessments.
Can I use SCCAI for Crohn's disease?
SCCAI was validated for ulcerative colitis and colonic Crohn's disease but not small-bowel Crohn's. For Crohn's disease affecting the ileum or ileocolon, use the Crohn's Disease Activity Index (CDAI) or Harvey-Bradshaw Index (HBI). SCCAI can be used as a supplementary measure in colonic Crohn's but is not standard.
What if my patient has SCCAI <3 but elevated CRP?
This discordance is common, occurring in up to 25% of UC patients. Elevated CRP with low SCCAI suggests subclinical or ongoing inflammation not manifesting as symptoms. This patient likely needs either (1) more frequent monitoring with consideration of biologic escalation, or (2) endoscopy to assess mucosal healing. Do not assume remission on SCCAI alone.
How often should SCCAI be measured?
During induction therapy (e.g., high-dose corticosteroids), measure SCCAI every 1–2 weeks to detect early response. Once in remission (SCCAI <3), measure every 4–8 weeks during maintenance to detect early flare. If symptoms recur, measure immediately. Between-visit phone check-ins using SCCAI can improve flare detection.
Is SCCAI accurate if the patient is taking antidiarrheals?
No. Antidiarrheals artificially reduce stool frequency, lowering the SCCAI. If a patient is taking loperamide, request discontinuation 2–3 days before SCCAI measurement, or note the SCCAI as approximate. Always verify the stool frequency score with the patient's actual diary, not recalled averages.
Sources
- Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32. DOI: 10.1136/gut.43.1.29 ↗
How to cite this page
ScholarGate. (2026, June 3). Simple Clinical Colitis Activity Index. ScholarGate. https://scholargate.app/en/gastroenterology/sccai
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Crohn's Disease Activity IndexGastroenterology↔ compare
- Harvey-Bradshaw IndexGastroenterology↔ compare
- Mayo ScoreGastroenterology↔ compare
- Short Inflammatory Bowel Disease QuestionnaireGastroenterology↔ compare